Zacks Investment Research downgraded shares of Trupanion (NASDAQ:TRUP) from a buy rating to a hold rating in a report released on Thursday.

According to Zacks, “Trupanion, Inc. operates as a direct-to-consumer monthly subscription service provider of a medical insurance plan for cats and dogs. It operates primarily in Canada, Puerto Rico, and the United States. The Company serves pet owners and veterinarians. Trupanion, Inc. is headquartered in Seattle, Washington. “

Several other research analysts have also weighed in on the company. BidaskClub raised Trupanion from a hold rating to a buy rating in a research report on Tuesday, November 27th. ValuEngine upgraded Trupanion from a hold rating to a buy rating in a research note on Wednesday, November 21st. CL King upgraded Trupanion from a neutral rating to a buy rating in a research note on Tuesday, October 2nd. Finally, Canaccord Genuity reiterated a buy rating and issued a $43.00 price target on shares of Trupanion in a research note on Tuesday, November 13th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $44.89.

NASDAQ:TRUP traded down $0.57 on Thursday, reaching $27.10. The company’s stock had a trading volume of 137,478 shares, compared to its average volume of 257,435. Trupanion has a 12-month low of $22.38 and a 12-month high of $46.70. The company has a quick ratio of 1.80, a current ratio of 1.80 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $912.70 million, a P/E ratio of -389.43 and a beta of 1.23.

Trupanion (NASDAQ:TRUP) last released its quarterly earnings data on Thursday, November 8th. The financial services provider reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. Trupanion had a negative return on equity of 2.45% and a negative net margin of 0.52%. The business had revenue of $78.16 million during the quarter, compared to analysts’ expectations of $77.70 million. During the same period in the prior year, the firm posted $0.01 EPS. The business’s quarterly revenue was up 23.8% compared to the same quarter last year. Sell-side analysts anticipate that Trupanion will post -0.01 earnings per share for the current fiscal year.

In other news, insider Darryl Rawlings sold 85,053 shares of the stock in a transaction on Thursday, November 15th. The shares were sold at an average price of $23.61, for a total transaction of $2,008,101.33. Following the completion of the sale, the insider now owns 1,555,997 shares of the company’s stock, valued at $36,737,089.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Tricia Plouf sold 1,300 shares of the stock in a transaction on Friday, November 30th. The stock was sold at an average price of $30.00, for a total transaction of $39,000.00. Following the sale, the chief financial officer now directly owns 1,300 shares of the company’s stock, valued at approximately $39,000. The disclosure for this sale can be found here. Insiders have sold 342,265 shares of company stock worth $8,719,518 over the last quarter. 20.70% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in TRUP. SG Americas Securities LLC acquired a new position in shares of Trupanion in the 2nd quarter worth approximately $100,000. Tower Research Capital LLC TRC acquired a new position in shares of Trupanion during the 3rd quarter valued at $118,000. US Bancorp DE lifted its position in shares of Trupanion by 111.8% during the 2nd quarter. US Bancorp DE now owns 4,512 shares of the financial services provider’s stock valued at $175,000 after acquiring an additional 2,382 shares during the period. Jane Street Group LLC acquired a new position in shares of Trupanion during the 3rd quarter valued at $231,000. Finally, Atlantic Trust LLC bought a new stake in Trupanion during the 2nd quarter valued at $251,000. Hedge funds and other institutional investors own 95.68% of the company’s stock.

About Trupanion

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels.

Further Reading: Institutional Investors

Get a free copy of the Zacks research report on Trupanion (TRUP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Trupanion (NASDAQ:TRUP)

Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.